Discover Great Companies Discover Great Clients
Popularity  3643   |   Likes  1   |   Feedback  1 Claim this company
Suzhou Taicang City Jiangsu Sheng Wu Ke Ji / Biotechnology Engineering Biological Products Enzymes Engineering Pharmaceutical Industrial Biotechnology Pharmaceuticals Biotechnology Compositing He Gan Acids He Suan Yao Products Fa Jiao Gong Yi Vaccines Technology Pharmaceutical Technology Zhen Duan Yong Yao 科技型中小企业 省科技型中小企业 高新技术企业 省级高新技术企业 发明专利 专精特新小巨人企业
More

Company Overview

  • Nature: Joint Venture Size: 50-99 employees Founded: 14年
  • Industry: Pharmaceuticals/Bioengineering
  • Full name: Jiangsu GenScript Probio Biotech Joint-stock Co., Ltd.。

Development Stage

  • Honors: 科技型中小企业 省科技型中小企业 According to algorithm

About the Company

Jiangsu GenScript Probio Biotech Joint-stock Co., Ltd. was established on March 29, 2012. It mainly applies synthetic biology and genetic engineering technologies to research, develop and produce virus-like particle (VLP) vaccines and diagnostic reagent enzyme products. Its registered address is in Taicang Biomedical Industrial Park, Suzhou, Jiangsu, with a registered capital of 41.2 million yuan. The founder of GenScript Probio, An Haiqian, and the core members have all received professional training at renowned universities in China and the United States and have many years of work experience at home and abroad. They have successful experience in operating multiple projects. Pragmatism, efficiency, integrity and innovation constitute the corporate culture of GenScript Probio. The company has built a genetic engineering enzyme preparation production platform, with a fermentation culture scale of 28,000 liters per batch and a production line capable of producing up to tens of kilograms of highly purified recombinant protein per batch. The annual capacity of recombinant protein freeze-dried powder exceeds 1,000 kilograms. At present, its main products, including recombinant proteinase K, broad-spectrum endonuclease, RNase and glucose oxidase, all have molecular invention patents. During the COVID-19 pandemic, GenScript Probio supplied hundreds of millions of test-person portions of proteinase K raw materials to nucleic acid diagnostic kit manufacturers at home and abroad, and in the later stage of the pandemic, 90% of its products were exported to the United States. GenScript Probio has passed certifications and qualifications including National High-tech Enterprise, Technology-based Private Enterprise, Jiangsu Province Enterprise Founded by High-level Overseas Talents, and Graduate and Undergraduate Internship Workstation. On the basis of the successful industrialization of recombinant protein diagnostic reagents, and relying on the synthetic biology and genetic engineering technology platforms of its Beijing company, GenScript Probio began in 2009 and first completed the research and development of an H1N1 influenza VLP vaccine. It subsequently developed a series of recombinant virus-like particle (VLP) vaccine products, among which the bivalent foot-and-mouth disease VLP vaccine has completed pilot testing and animal efficacy trials and has filed international PCT patents entering neighboring countries. This recruitment of GenScript Probio mainly aims to strengthen the research and development and production of genetically recombinant VLP vaccines, the research and development of novel mRNA vaccines, and the research and development of novel diagnostic reagents. The company plans to develop several recombinant VLP and mRNA vaccine products within 3-5 years. Therefore, the company's wholly-owned subsidiaries and branches in Shanghai and Beijing are recruiting vaccine and recombinant protein research and development talents with high salaries in Zhangjiang, Shanghai and Yizhuang, Beijing, to grow together with the company and become business partners of GenScript Probio. At present, GenScript Probio is actively advancing the industrialization of VLP vaccines, using its own funds, the capital market and local government support to jointly build a high-tech company oriented toward the development of VLP vaccines and mRNA vaccines, and gradually becoming an enterprise in China's novel genetically recombinant vaccine research, development and production. The company expects to be listed on major capital markets within 2-3 years.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 4,120万(元)
Legal Representative: 安海谦
Date Established:
Credit Code: 91320585592578120A
Registered Address: 太仓市沙溪镇生物医药产业园

People who follow this company also follow

Competitors (Similar Companies)

“To develop high-quality biologics that are accessible and affordable f”
生命科学 生物信息 生物制药 干细胞
“A high-tech biological feed group enterprise integrating scientific re”
“To become an authoritative institution for metabolomics small-molecule”
“One of the first China Time-honored Brands”
“Committed to the independent R&D, production, and sales of innovative ”
医药 生物科技/生物工程 生物医药 细胞治疗
“A high-tech enterprise focusing on recombinant protein application sol”
医药 生物制品 生物医药 抗体药

Discover Great Companies, Discover Great Clients

苏州公司名录 苏州“Taicang City”公司名录 苏州“生物科技/生物工程”公司名录 苏州“试剂”公司名录 苏州“诊断试剂”公司名录 苏州“生物医药”公司名录 苏州“疫苗”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates